{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:11:33Z","timestamp":1787235093516,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5,5]]},"abstract":"<jats:p>\n                    Approximately 1-third of patients with severe asthma are candidates for both omalizumab and mepolizumab treatment. We aimed to compare the clinical, spirometric and inflammatory efficacy of these 2 biologics in atopic and eosinophilic \u201coverlap\u201d severe asthma patients. In our 3-center retrospective cross-sectional observational study, the data of patients who received omalizumab or mepolizumab for at least 16 weeks to treat severe asthma were examined. Atopic (perennial allergen sensitivity and total IgE level 30\u20131500 IU\/mL) and eosinophilic (blood eosinophil counts \u2265150 cells\/\u00b5L in admission; or \u2265300 cells\/\u00b5L in the previous year) patients with asthma suitable for both biologics were included in the study. Post-treatment changes in the asthma control test (ACT) score, number of attacks, forced expiratory volume in 1 second (FEV1), and eosinophil count were compared. The rates of any biological responder patient were compared according to whether they had high eosinophil counts (\u2265500 cells\/\u00b5L vs &lt;500 cells\/\u00b5L). Total of 181 patients data were evaluated, of the 74 atopic and eosinophilic overlap patients included in the study, 56 were receiving omalizumab and 18 were receiving mepolizumab. When omalizumab and mepolizumab treatment efficacies were compared, there was no difference in terms of the reduction in attacks and improvement in ACT. The decrease in eosinophil levels in patients in the mepolizumab arm was significantly higher than that in patients in the omalizumab arm (46.3% vs 87.8%;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; .001). The improvement in FEV1 was greater with mepolizumab treatment, although the difference was not significant (215\u2009mL vs 380\u2009mL;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = .053). It has been shown that having high eosinophil counts does not affect the clinical and spirometric responder patient rates for either biological condition. The success of omalizumab and mepolizumab treatment is similar in patients with atopic and eosinophilic overlap with severe asthma. However, because the baseline patient inclusion criteria are not compatible, head-to-head studies comparing both biological agents are required.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000033660","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T10:03:38Z","timestamp":1683281018000},"page":"e33660","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of omalizumab and mepolizumab treatment efficacy in patients with atopic and eosinophilic \u201cOverlap\u201d severe asthma: Biological agent preference in atopic-eosinophilic severe asthma"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9794-5662","authenticated-orcid":false,"given":"Fatma Merve","family":"Tepetam","sequence":"first","affiliation":[{"name":"University of Health Sciences, S\u00fcreyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Immunology and Allergy, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Burkan","family":"Akyildiz","sequence":"additional","affiliation":[{"name":"University of Health Sciences, S\u00fcreyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Immunology and Allergy, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eeyma","family":"\u00d6zden","sequence":"additional","affiliation":[{"name":"University of Health Sciences, S\u00fcreyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Immunology and Allergy, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihan","family":"\u00d6rcen","sequence":"additional","affiliation":[{"name":"University of Health Sciences, Derince Training and Research Hospital, Kocaeli, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu\u011f\u00e7e","family":"Yakut","sequence":"additional","affiliation":[{"name":"University of Health Sciences, Diyarbakir Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zge","family":"Atik","sequence":"additional","affiliation":[{"name":"University of Health Sciences, S\u00fcreyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Immunology and Allergy, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.200401-033OC","article-title":"Can guideline-defined asthma control be achieved? The gaining optimal asthma control study.","volume":"170","author":"Bateman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma.","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0140-6736(17)33311-1","article-title":"Asthma.","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"R5-20250504","first-page":"30146","article-title":"Advancing the care of severe asthma: differential diagnosis, multidisciplinary management, and patient engagement.","volume":"S0002-9343","author":"Corren","year":"2019","journal-title":"Am J Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","article-title":"Cluster analysis and clinical asthma phenotypes.","volume":"178","author":"Haldar","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","article-title":"Identification of asthma phenotypes using cluster analysis in the severe asthma research program.","volume":"181","author":"Moore","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12931-015-0299-y","article-title":"Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study.","volume":"16","author":"Silkoff","year":"2015","journal-title":"Respir Res"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12890-022-01856-9","article-title":"Prevalence of eosinophilic, atopic, and overlap phenotypes among patients with severe asthma in Saudi Arabia: a cross-sectional study.","volume":"22","author":"Al-Jahdali","year":"2022","journal-title":"BMC Pulm Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/02770903.2017.1322611","article-title":"Biologic treatment eligibility for real-world patients with severe asthma: the IDEAL study.","volume":"55","author":"Albers","year":"2018","journal-title":"J Asthma"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaci.2004.11.053","article-title":"The antiinflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.","volume":"115","author":"Holgate","year":"2005","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl 2","key":"R12-20250504","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000350852","article-title":"Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma.","volume":"161","author":"Takaku","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2147\/DDDT.S130743","article-title":"Targeted therapy in severe asthma today: focus on immunoglobulin E.","volume":"11","author":"Pelaia","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fmed.2017.00093","article-title":"The biology of eosinophils and their role in asthma.","volume":"4","author":"McBrien","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1183\/09059180.00004013","article-title":"Anti-interleukin-5 therapy in severe asthma.","volume":"22","author":"Garcia","year":"2013","journal-title":"Eur Respir Rev"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma.","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.","volume":"360","author":"Nair","year":"2009","journal-title":"N Engl J Med"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.rmed.2016.12.009","article-title":"Comparative effectiveness of mepolizumab and omalizumab in severe asthma: an indirect treatment comparison.","volume":"123","author":"Cockle","year":"2017","journal-title":"Respir Med"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/02770903.2017.1306548","article-title":"Omalizumab versus Mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: a network meta-analysis.","volume":"55","author":"Nachef","year":"2018","journal-title":"J Asthma"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/cea.13882","article-title":"Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes.","volume":"51","author":"Fong","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.rmed.2019.06.004","article-title":"Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.","volume":"154","author":"Humbert","year":"2019","journal-title":"Respir Med"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"AB21","DOI":"10.1016\/j.jaci.2022.12.070","article-title":"Real-world benefits of mepolizumab in patients with overlapping allergic and eosinophilic endophenotypes: post hoc analysis of REALITI-A by omalizumab eligibility.","volume":"151","author":"Lee","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.rmed.2013.04.017","article-title":"The eXpeRience registry: the \u201creal-world\u201d effectiveness of omalizumab in allergic asthma.","volume":"107","author":"Braunstahl","year":"2013","journal-title":"Respir Med"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1902345","DOI":"10.1183\/13993003.02345-2019","article-title":"Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme.","volume":"55","author":"Taill\u00e9","year":"2020","journal-title":"Eur Respir J"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"2000151","DOI":"10.1183\/13993003.00151-2020","article-title":"Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis.","volume":"56","author":"Harrison","year":"2020","journal-title":"Eur Respir J"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.anai.2019.11.016","article-title":"Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma.","volume":"124","author":"Busse","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/all.12914","article-title":"Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.","volume":"71","author":"Magnan","year":"2016","journal-title":"Allergy"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study.","volume":"7","author":"Casale","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"101836","DOI":"10.1016\/j.pupt.2019.101836","article-title":"One year of mepolizumab. Efficacy and safety in real-life in Italy.","volume":"58","author":"Bagnasco","year":"2019","journal-title":"Pulm Pharmacol Ther"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5578\/tt.20219905","article-title":"The significance of eosinophil and eosinophil lymphocyte ratio (ELR) in predicting response to omalizumab treatment in patients with severe allergic asthma.","volume":"69","author":"\u00d6zgen","year":"2021","journal-title":"Tuberk Toraks"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033660","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T21:06:27Z","timestamp":1746306387000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":30,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033660","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,5]]}}}